EU-Taiwan seminar explores GenAI’s copyright challenges and licensing solutions ahead of 2025 regulations
In November 2022, ChatGPT’s launch marked the beginning of a global surge in generative AI (GenAI) development. However, since then,…
LLM proliferation drives edge market growth, benefiting IPC vendors
The widespread market adoption of artificial intelligence (AI) has prompted various industries to seek AI applications for transformation and efficiency…
FDA approves durvalumab for muscle invasive bladder cancer
On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment,…
FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors
Today, the U.S. Food and Drug Administration approved a novel treatment for hemophilia A or B, with or without factor…
Scientific Public Private Partnerships and Consortia
Find out how CDER works with partners and consortia to identify science gaps in drug development
FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication
On March 28, 2025, the Food and Drug Administration expanded the indication for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis…
Hyundai’s $21B US bet features supply chain localization
The automaker plans to build a $5.8 billion steel plant in Louisiana as part of the investment.
Trump’s tariffs: Tracking the status of international trade actions
The U.S. has rolled out a deluge of tariffs, sparking responses from trading partners. Here’s where each tariff – threatened…
C3TI Areas of Interest
C3TI’s areas of interest span drug development programs, therapeutic areas, and disciplines. Learn more.
J. Jill plans ship-from-store capability
The apparel brand will join a growing roster of retailers using their brick-and-mortar footprints to fulfill e-commerce orders.